MARKET

HSDT

HSDT

HELIUS MEDICAL
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4176
-0.0037
-0.88%
Closed 16:00 09/18 EDT
OPEN
0.4200
PREV CLOSE
0.4213
HIGH
0.4348
LOW
0.4100
VOLUME
231.13K
TURNOVER
--
52 WEEK HIGH
1.840
52 WEEK LOW
0.2490
MARKET CAP
18.84M
P/E (TTM)
-0.6486
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain Injury
NEWTOWN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the publication of an important, peer-reviewed study titled Translingual Neural Stimulation with
GlobeNewswire · 09/08 12:05
Helius Medical Technologies, Inc. Announces Publication Of Peer-Reviewed Study In EMJ Radiology
NEWTOWN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today
Benzinga · 09/08 11:10
LD Micro 360 Companies --Set to Present this Week.
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
ACCESSWIRE · 09/02 22:21
Helius Medical Technologies, Inc. to Present at Three Upcoming Investor Conferences in September
GlobeNewswire · 08/31 19:00
Helius Medical Technologies, Inc. Announces Departure of President, Chief Executive Officer and Chairman Philippe Deschamps; Board of Directors Appoints Dane C. Andreeff as Interim President and Chief Executive Officer and Appoints Blane Walter as Chairman of the Board of Directors
NEWTOWN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Philippe Deschamps, has stepped down from his positions as President and Chief Executive Officer
GlobeNewswire · 08/25 12:05
Helius Medical Technologies, Inc. Announces Departure of President, Chief Executive Officer and Chairman Philippe Deschamps; Board of Directors Appoints Dane C. Andreeff as Interim President and Chief Executive Officer and Appoints Blane Walter as Chairman of the Board of Directors
Benzinga · 08/25 11:16
Helius Medical Tech Q2 EPS $(0.08) Down From $(0.01) YoY, Sales $100.00K Down From $518.00K YoY
Helius Medical Tech (NASDAQ: HSDT) (TSX: HSM) reported quarterly losses of $(0.08) per share. This is a 700 percent decrease over losses of $(0.01) per share from the same period last year.
Benzinga · 08/12 20:20
Helius Medical Technologies EPS beats by $0.04, beats on revenue
Helius Medical Technologies (HSDT): Q2 GAAP EPS of -$0.08 beats by $0.04.Revenue of $0.13M (-75.0% Y/Y) beats by $0.03M.Press Release
Seekingalpha · 08/12 20:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HSDT stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 3.58M
% Owned: 7.95%
Shares Outstanding: 45.11M
TypeInstitutionsShares
Increased
6
687.64K
New
15
-2.80M
Decreased
7
98.04K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.87%
Healthcare Equipment & Supplies
-0.40%
Key Executives
Chairman/President/Chief Executive Officer/Director
Philippe Deschamps
Chief Financial Officer/Chief Operating Officer
Joyce LaViscount
Other
Jonathan Sackier
Director
Mitchell Tyler
Independent Director
Dane Andreeff
Independent Director
Thomas Griffin
Independent Director
Huaizheng Peng
Director
Mitch Tyler
Independent Director
Edward Straw
Independent Director
Blane Walter
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average HSDT stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HSDT
Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company’s offered product is portable neuromodulation stimulator (PoNS) device. PoNS is an authorized class II, non-implantable, medical device in Canada intended for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Helius Medical Technologies Inc stock information, including NASDAQ:HSDT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSDT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSDT stock methods without spending real money on the virtual paper trading platform.